OMDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Omada Health Inc (OMDA) is not a strong buy at this time for a beginner investor seeking long-term growth. The stock shows weak technical indicators, lacks positive trading signals, and has mixed financial performance. While the company has strong revenue growth, its declining net income and EPS, along with bearish technical trends, suggest caution. The lack of recent positive news or catalysts further supports a hold recommendation.
The technical indicators for OMDA are bearish. The MACD is negative and contracting, RSI is neutral at 20.143, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below the key pivot level of 12.661, with support at 10.782 and resistance at 14.541.
The company reported strong revenue growth in Q3 2025, up 49.47% YoY, and an improved gross margin of 66.25%, up 5.58% YoY.
Bearish technical indicators and lack of significant trading trends from hedge funds or insiders. No recent news or congress trading data to act as a catalyst.
In Q3 2025, Omada Health reported revenue of $68.03M, up 49.47% YoY. However, net income dropped to -$3.18M (-65.55% YoY), and EPS declined to -0.06 (-64.71% YoY). Gross margin improved to 66.25%, up 5.58% YoY.
Analysts have lowered price targets recently. Goldman Sachs reduced the target from $33 to $29 and then to $26, while maintaining a Buy rating. Barclays lowered its target from $29 to $22, keeping an Overweight rating. Wells Fargo initiated coverage with an Equal Weight rating and a $17 price target, citing balanced risk/reward but concerns over client concentration and ownership structure.
